Boyu Capital is a private equity firm that invests in consumer, retail, media and technology, healthcare, and financial services sectors.
Business Model: B2C
Revenue: $5M
Employees: 11-50
Address: 88 Queensway
City: Hong Kong
State: other
Zip:
Country: HK
Boyu Capital Consultancy Co. Ltd is a private equity firm specializing in investments in China. Boyu Capital Consultancy Co. Ltd was founded on September 28, 2010 and is based in Hong Kong with an additional office in Beijing, China.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
6/2014 | COFCO | Post-IPO Equity | - |
12/2022 | ArriVent Biopharma | Series B | 0 |
11/2020 | D3 Bio | Series A | 200M |
6/2022 | Evat Master | Series A | 0 |
12/2021 | Jinke | Post-IPO Equity | 478.6M |
2/2014 | LY.com | Series C | 82.3M |
7/2016 | CStone Pharmaceuticals | Series A | 150M |
8/2018 | KLOOK | Series D | 200M |
8/2021 | MediTrust Health | Series C | 308.3M |
12/2021 | Recurrent.ai | Venture Round | 38M |
7/2020 | Antengene Corporation | Series C | 97M |
11/2018 | NetEase Cloud Music | Series B | 600M |
12/2019 | Kuaishou Technology | Series F | 3B |
8/2021 | Zeekr | Series A | 500M |
7/2018 | Trax | Series D | 0 |
11/2021 | J&a;T Express | Private Equity Round | 0 |
8/2020 | Yuanfudao | Series G | 1.2B |
2/2018 | Viela Bio | Series A | 0 |
11/2021 | Vision Medicals | Series D | 47M |
2/2017 | iQiyi | Series G | 1.5B |
7/2018 | Curon Biopharma | Series A | 150M |
7/2018 | MEGVII | Series D | - |
9/2021 | XSKY Data Technology | Series E | 0 |
8/2021 | Pulse Medical Technology | Series C | 0 |
9/2018 | LianLian Pay | Venture Round | 146.6M |
3/2022 | MoreSec | Series D | 0 |
5/2022 | Shuaike Pet Food Products | Private Equity Round | 0 |
6/2021 | RecBio | Series C | 156.3M |
1/2021 | KLOOK | Series E | 0 |
9/2017 | LifeMine Therapeutics | Series A | 0 |
11/2017 | Berry Oncology | Series A | 121.2M |
9/2019 | Chengjia Apartment | Series A | 300M |
12/2020 | SciNeuro | Series A | 100M |
4/2021 | J&a;T Express | Private Equity Round | 2B |
5/2013 | Berry Genomics | Series B | 14.7M |
8/2021 | MediTrust Health | Series C | 0 |
5/2018 | China Chengxin Credit | Series A | 0 |
10/2021 | WT Microtech Medical | Series E | 153M |
1/2019 | Yimidida | Series D | 266.1M |
9/2012 | Alibaba Group | Private Equity Round | 0 |
5/2018 | Brii Biosciences | Venture Round | 260M |
3/2020 | Yuanfudao | Series G | 1B |
3/2020 | Pinduoduo | Post-IPO Equity | 1.1B |
6/2019 | Waterdrop | Series C | 144.6M |
4/2021 | Adcentrx Therapeutics | Series A | 50M |
9/2022 | Animoca Brands | Convertible Note | 110M |
5/2018 | CStone Pharmaceuticals | Series B | 260M |
3/2020 | Yatsen Holding | Series D | 240M |
11/2021 | Positive Sequence Biology | Series A | 0 |
6/2022 | Frontera Therapeutics | Series B | 0 |
2/2022 | ArriVent Biopharma | Series A | 69M |
1/2021 | 4Paradigm | Series D | 0 |
1/2021 | Lalamove | Series F | 1.5B |
11/2021 | Edge Medical Robotics | Series C | 0 |
1/2019 | Antengene Corporation | Series B | 0 |
8/2021 | Abogen Biosciences | Series C | 0 |
6/2021 | ArriVent Biopharma | Series A | 81M |
6/2022 | Frontera Therapeutics | Series B | 0 |
6/2022 | Evat Master | Series A | 0 |
5/2022 | Shuaike Pet Food Products | Private Equity Round | 0 |
3/2022 | MoreSec | Series D | 0 |
2/2022 | ArriVent Biopharma | Series A | 0 |
12/2021 | Recurrent.ai | Venture Round | 0 |
12/2021 | Jinke | Post-IPO Equity | 0 |
11/2021 | Vision Medicals | Series D | 0 |
11/2021 | J&a;T Express | Private Equity Round | 0 |
11/2021 | Positive Sequence Biology | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|